Brandon Couillard

Jack Meehan

Tycho Peterson

Conor Noel McNamara

Daniel Leonard

Patrick Donnelly

Dan Leonard

David Carter

Matt Taylor

- Bio-Rad's digital PCR (dPCR) business, particularly its Droplet Digital PCR (ddPCR) technology, has evolved significantly since its commercialization in **2010** with the QX100 system, providing **absolute quantitation of nucleic acids** through droplet-based partitioning.  **[12208_tx_376151_1]** **[12208_tx_376151_2]** 
- The company estimates the digital PCR market at approximately **$600 million**, with Bio-Rad holding about **half of this market**.  **[12208_tx_376151_8]** **[12208_tx_376151_11]**  Bio-Rad has expanded its product portfolio with the new **QX Continuum** and **QX700 series** platforms, designed to accelerate dPCR adoption through accessible price points and simplified workflows.  **[12208_tx_376151_5]** **[12208_tx_376151_3]** 
- Bio-Rad has raised its **2025 growth guidance to mid-single digits** and projects **long-term growth rates potentially in the high single digits** for this segment.  **[12208_tx_376151_8]**  This growth is supported by an industry-leading catalog of over **490,000 validated assays**, with an additional **600,000 assays** validated for both qPCR and ddPCR to be released in **early 2026**.  **[12208_tx_376151_6]**

Bio-Rad Laboratories Inc. Discusses Digital PCR Business and Market Expansion

BIO-RAD LABORATORIES (BIO)